Document is current
Any future updates will be listed below
-
Authors
Berkell, Matilda http://orcid.org/0000-0002-7096-7896
Mysara, Mohamed http://orcid.org/0000-0001-5746-4330
Xavier, Basil Britto http://orcid.org/0000-0002-5897-0240
van Werkhoven, Cornelis H. http://orcid.org/0000-0002-0626-4635
Monsieurs, Pieter
Lammens, Christine
Ducher, Annie
Vehreschild, Maria J. G. T. http://orcid.org/0000-0003-0446-3224
Goossens, Herman
de Gunzburg, Jean http://orcid.org/0000-0001-8049-9283
Bonten, Marc J. M.
Malhotra-Kumar, Surbhi http://orcid.org/0000-0001-8699-8905
,
Engbers, Annemarie
de Regt, Marieke
Biehl, Lena M.
Cornely, Oliver A.
Jazmati, Nathalie
Bouverne, Marie-Noelle
Sablier-Gallis, Frederique
Mentré, France
Merle, Uta
Stallmach, Andreas
Rupp, Jan
Bogner, Johannes
Lübbert, Christoph
Silling, Gerda
Witzke, Oliver
Gikas, Achilleas
Maraki, Sofia
Daikos, George
Tsiodras, Sotirios
Skoutelis, Athanasios
Sambatakou, Helen
Pujol, Miquel
Dominguez-Luzon, M. Angeles
Aguado, Jose M.
Bouza, Emilio
Cobo, Javier
Rodríguez-Baño, Jesús
Almirante, Benito
de la Torre Cisneros, Julian
Florescu, Simin A.
Nica, Maria
Vata, Andrei
Hristea, Adriana
Lupse, Mihaela
Herghea, Delia
Postil, Deborah
Barraud, Olivier
Molina, Jean-Michel
De Lastours, Victoire
Guimard, Thomas
Talarmin, Jean-Philippe
Duval, Xavier
Bernard, Louis
Launay, Odile
- License Information
-
More Information
Article History
Received: 11 June 2020
Accepted: 3 March 2021
First Online: 14 April 2021
Competing interests
: C.H.v.W. received speaker fees from Pfizer and Merck/MSD, and non-financial research support from bioMérieux. A.D. is an employee and shareholder of Da Volterra. J.d.G. is a consultant and shareholder of Da Volterra. M.J.G.T.V. has received research grants from 3M, Astellas Pharma, Da Volterra, Gilead Sciences, Glycom, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics; speaker fees from Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer and has been a consultant to Alb Fils Kliniken GmbH, Astellas Pharma, Da Volterra, Ferring, MaaT Pharma, Merck/MSD and Summit Therapeutics. M.B., M.M., B.B.X., C.L., P.M., M.J.M.B., H.G., S.M.-K. report no competing interests.
